Launched on 06/23/2005, the Invesco Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ETFs? The ...

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ...

A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart ...

Biotech and drug-innovation themes continue to dominate markets—from AI-driven drug discovery to blockbuster obesity treatments—and a new ETF filing suggests asset managers want a piece of that ...

The first strong outlook factor for IHE is its inclusion of Eli Lilly at almost 27% weight. The pharmaceutical company has seen tremendous growth due to Mounjaro, approved by the FDA in 2022, and ...

The current generation of deals, which is likely to involve AbbVie (NYSE: ABBV), Merck & Co Inc (NYSE: MRK), Bristol-Myers Squibb Co (NYSE: BMY), and Gilead Sciences Inc (NYSE: GILD), is focused on ...

Yet here’s the kicker: ETFs heavy on Eli Lilly could end up in a position of strength. Thanks to the extraordinary success of Mounjaro and Zepbound, which have generated $25 billion in the first nine ...

VanEck Pharmaceutical ETF (PPH) surged 26% over the past year driven by weight-loss drug demand. Eli Lilly and Novo Nordisk combine for 27% of holdings. Analysts expect the GLP-1 market to exceed ...

Sovereign wealth funds once appeared only intermittently in life-science financing. Their money surfaced through venture funds or private equity partnerships, usually at one remove from the operating ...